Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Rush University Medical Center
Canadian Cancer Trials Group
The Methodist Hospital Research Institute
Children's Oncology Group
Duke University
NYU Langone Health
City of Hope Medical Center
Pediatric Brain Tumor Consortium